US 10,159,746 B2  4  3  such compounds can be significantly reduced and, in some  cases, may even be eliminated.  In one aspect, methods for preparing a pharmaceutical  composition are featured, which include:  (a) one (or more) peptide proteasome inhibitors (e.g., a  compound of formula (1)-(5) or a pharmaceutically  acceptable salt thereof);  (b) one or more cyclodextrins ("CDs"); and  ( c) water;  (i) providing a first combination that includes:  wherein the first combination is heterogeneous and the  compound or salt has a low solubility in the first  combination; and  (ii) contacting the first combination with an acid to form  a second combination, wherein the compound is more  soluble in the second combination than in the first combi- nation.  In another aspect, methods for preparing a pharmaceutical  composition are featured, which include:  (i) providing a first combination that includes:  (a) a compound:  (b) one or more cyclodextrins ("CDs"); and  (c) water;  wherein the first combination is heterogeneous and the  compound or salt has a low solubility in the first  combination; and  or a pharmaceutically acceptable salt thereof;  (ii) contacting the first combination with an acid to form  a second combination, wherein the compound is more  soluble in the second combination than in the first combi- nation.  In a further aspect, methods for preparing a pharmaceu- tical composition are featured, which include:  (i) providing a first combination that includes:  (a) a compound:  (ii) contacting the first combination with an aqueous  solution of citric acid to form a second combination, wherein  the compound is more soluble in the second combination  than in the first combination.  In one aspect, pharmaceutical compositions are featured,  which are prepared by any one of the methods described  herein.  In one aspect, methods for treating cancer (e.g., multiple  myeloma, e.g., multiple myeloma that is relapsed and/or  refractory) in a patient are featured, which include admin› istering to the patient a therapeutically effective amount of  a pharmaceutical composition prepared by any one of the  methods described herein.  In another aspect, methods for treating autoimmune dis› ease in a patient are featured, which include administering to  the patient a therapeutically effective amount of a pharma› ceutical composition prepared by any one of the methods  described herein.  In another aspect, methods for treating graft or transplant- related condition in a patient are featured, which include  administering to the patient a therapeutically effective  amount of a pharmaceutical composition prepared by any  one of the methods described herein.  In another aspect, methods for treating neurodegenerative  disease in a patient are featured, which include administer› ing to the patient a therapeutically effective amount of a  pharmaceutical composition prepared by any one of the  methods described herein.  In another aspect, methods for treating fibrotic-associated  condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a  pharmaceutical composition prepared by any one of the  methods described herein.  In another aspect, methods for treating fibrotic-associated  condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a  pharmaceutical composition prepared by any one of the  methods described herein.  In another aspect, methods for treating ischemic-related  condition in a patient are featured, which include adminis› tering to the patient a therapeutically effective amount of a  pharmaceutical composition prepared by any one of the  methods described herein.  In another aspect, methods for treating an infection in a  patient are featured, which include administering to the  patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods  described herein.  In another aspect, methods for treating an infection in a  patient are featured, which include administering to the  patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods  described herein.  In another aspect, methods for treating disease associated  with bone loss in a patient are featured, which include  administering to the patient a therapeutically effective  amount of a pharmaceutical composition prepared by any  one of the methods described herein.  In another aspect, methods for treating an infection in a  patient are featured, which include administering to the  patient a therapeutically effective amount of a pharmaceu› tical composition prepared by any one of the methods  described herein.  Embodiments can include one or more of the following  features.  The first combination does not include appreciable  amounts of any organic solvent(s). In some embodiments,  or a pharmaceutically acceptable salt thereof;  (b) SBECD; and  (c) water for injection;  wherein the first combination is heterogeneous and the  compound or salt has a low solubility in the first  combination; and 